Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Relapsed or Refractory NK/T Cell Lymphoma
NCT03107962Phase 2Unknown
- Start
- Feb 2017
- Primary completion
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in natural killer/T-cell lymphoma (NKTL). Primary endpoint: Response Rate at 18 weeks. Status: unknown.
02
Drugs
03
Conditions
natural killer/T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT03107962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03107962.